STMN2: A Potential Drug Target for Neurological Disorders (G11075)

Target Name: STMN2

NCBI ID: G11075

STMN2

STMN2: A Potential Drug Target for Neurological Disorders

Neuronal growth-associated protein (silencer element) (STMN2) is a protein that has been identified as a potential drug target and biomarker for a variety of neurological and psychiatric disorders. STMN2 is a non-coding RNA molecule that is expressed in a variety of tissues, including the brain, and is known for its role in neuronal development, differentiation, and survival.

Recent studies have identified STMN2 as a potential drug target for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. These studies have shown that STMN2 is involved in the development and progression of these disorders, and that inhibiting its activity may be a effective way to treat these conditions.

One of the reasons why STMN2 has been identified as a potential drug target is its role in the development and progression of neurodegenerative disorders.Neurodegenerative disorders are a group of conditions that are characterized by the progressive loss of neurons and their supporting cells. These disorders include Alzheimer's disease, Parkinson's disease, and schizophrenia.STMN2 has been shown to be involved in the development and progression of these disorders by promoting the formation of toxic neural cell aggregates and by inhibiting the clearance of neuroblasts.

Another reason why STMN2 has been identified as a potential drug target is its role in the development and progression of psychiatric disorders. Psychiatric disorders are a group of conditions that are characterized by the presence of symptoms such as anxiety, depression, and psychosis.STMN2 has been shown to be involved in the development and progression of these disorders by regulating the activity of neurotransmitter systems and by modulating the expression of genes involved in stress response.

In addition to its role in neurodegenerative and psychiatric disorders, STMN2 has also been shown to be involved in a variety of other processes in the brain, including cell survival, migration, and synaptic plasticity. These studies suggest that STMN2 may be a useful target for the development of new treatments for a variety of neurological and psychiatric disorders.

Overall, STMN2 is a protein that has the potential to be a drug target and biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: Stathmin 2

Functions: Regulator of microtubule stability. When phosphorylated by MAPK8, stabilizes microtubules and consequently controls neurite length in cortical neurons. In the developing brain, negatively regulates the rate of exit from multipolar stage and retards radial migration from the ventricular zone (By similarity)

The "STMN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STMN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets